



## **OxSonics Therapeutics**

(“OxSonics Therapeutics” or the “Company”)

### **OxSonics Signs Evaluation Agreement with Large Pharma Company**

**Oxford, UK – 9<sup>th</sup> December 2020** – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that it has entered into an evaluation agreement with a Large Pharma company to explore the potential use of the Company’s proprietary SonoTran® Platform with a novel anti-cancer therapeutic agent.

“We are very excited to be collaborating with this Large Pharma company, a company developing highly innovative therapies for the treatment of cancer,” said Colin Story, OxSonics Therapeutics Co-founder and CEO. “This collaboration follows our strategy of applying the SonoTran Platform across in-house and partnered programs to maximise its combination with multiple drug classes and use in multiple patient groups.”

The collaboration will focus on the combination of the Company’s SonoTran Platform with a novel undisclosed clinical-stage anti-cancer therapeutic being developed by the Large Pharma company. Financial terms of the agreement are not being disclosed.

The agreement is in line with OxSonics Therapeutics’ strategy of collaborating with pharmaceutical and biotechnology companies to significantly enhance the tumour penetration of anti-cancer therapies such as antibodies, antibody drug conjugates (ADCs), oncolytic viruses, and small molecules across a broad range of solid tumour cancer types. The SonoTran Platform can be utilised to solve a variety of unmet challenges not only related to efficacy, but also dose limiting toxicity and the enablement of optimal administration routes. Crucially, SonoTran avoids delays and development costs associated with drug reformulation making it an attractive proposition for the de-risking of clinical programs.

- ENDS -

### **About OxSonics Therapeutics**

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.



OxSonics is based in Oxford in the UK.

For more information please visit: [www.oxsonics.com](http://www.oxsonics.com).